Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.35 |
| ▸ | NPY1R | P25929 | 10/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.35 |
| ▸ | NPY2R | P49146 | 6/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627262 | 0.84 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL4587709 | 0.83 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL2815692 | 0.83 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL187696 | 0.82 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL2116832 | 0.82 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL29476474 | 0.82 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL7764489 | 0.82 | C3AR1 (0.41) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL6680407 | 0.82 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2815688 | 0.81 | C3AR1 (0.44) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL4587702 | 0.81 | C3AR1 (0.44) | NPY4RNPY1RNPY5RNPY2RC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1067879-B1 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | UNIV COLUMBIA (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20040038898-A1 | Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation | THE TRUSTEES OF COLUMBIA UNIVERSITY | 2004-02-26 | — | — | US | disclosed |
| US-6391300-B1 | INTRODUCING INTO EXTRACORPOREALLY CIRCULATING BLOOD FACTOR IXA COMPOUND WHICH IS GLU-GLY-ARG CHLOROMETHYL KETONE-INACTIVATED HUMAN FACTOR IXA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2002-05-21 | — | — | US | disclosed |
| EP-0907337-A4 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | UNIV COLUMBIA (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999049803-A9 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | UNIV COLUMBIA (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0907337-A1 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997042900-A9 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | — | 1998-03-05 | — | — | WO | disclosed |
| WO-1997042900-A1 | METHOD FOR INHIBITING THROMBOSIS IN A PATIENT WHOSE BLOOD IS SUBJECTED TO EXTRACORPOREAL CIRCULATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1997-11-20 | — | — | WO | disclosed |